Divis Laboratories Ltd vs Sanjivani Paranteral Ltd

A side-by-side comparison of Divis Laboratories Ltd (DIVISLAB) and Sanjivani Paranteral Ltd (SANJIVIN) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Divis Laboratories Ltd leads DIVISLAB vs SANJIVIN on 8 of 14 metrics (2 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

75.78
P/E ratio
21.81
11.59
P/B ratio
3.75
0.41%
Dividend yield
0.34%
₹96.73
EPS
₹6.81

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
20.30%
22.00%
Return on capital
28.46%
33.00%
EBITDA margin
14.75%
24.32%
Net margin
11.54%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
12.10%
Profit CAGR (3Y)

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.93L Cr
Market cap
₹189 Cr
₹10,560 Cr
Revenue
₹70 Cr
₹2,568 Cr
Net profit
₹8 Cr
0.00
Debt / equity
0.30
Divis Laboratories Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 11.5 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Sanjivani Paranteral Ltd
  • ["Promoter holding is low: 31.6%", "Company might be capitalizing the interest cost", "Debtor days have increased from 66.8 to 82.0 days."]
Divis Laboratories Ltd full analysis Sanjivani Paranteral Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

Divis Laboratories Ltd vs Sanjivani Paranteral Ltd: Share Price, Valuation & Which to Buy | DocStoX